Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation

Liver Transplantation

Volumn 18, Issue 7, 2012, Pages 803-810

  Sembera, Stepan ^a   Lammert, Craig ^a   Talwalkar, Jayant A ^a   Sanderson, Schuyler O ^a   Poterucha, John J ^a   Hay, J Eileen ^a   Wiesner, Russell H ^a   Gores, Gregory J ^a   Rosen, Charles B ^a   Heimbach, Julie K ^a   Charlton, Michael R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALLOPURINOL; AMANTADINE; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN A; DAPTOMYCIN; ERGOTAMINE; ERTAPENEM; FLUCONAZOLE; GABAPENTIN; GEMFIBROZIL; IMMUNOSUPPRESSIVE AGENT; MEDROXYPROGESTERONE; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFCILLIN; PAROXETINE; PRAVASTATIN; PREDNISONE; TACROLIMUS; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; DATA BASE; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; NAUSEA; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PRURITUS; RASH; RETRANSPLANTATION; SCLEROSING CHOLANGITIS; TOXIC HEPATITIS;

ADOLESCENT; ADULT; AGED; BIOPSY; CHILD; CHILD, PRESCHOOL; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; REOPERATION; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84863905084     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23424     Document Type: Article

References (27)

1. Watkins PB, Seeff LB,. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618-631.
2. Björnsson E,. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010; 32: 3-13.
3. Navarro VJ, Senior JR,. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.
4. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH,. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52: 730-742.
5. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al.; for Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
6. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al.; for Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
7. Ben-Ari Z, Pappo O, Mor E,. Intrahepatic cholestasis after liver transplantation. Liver Transpl 2003; 9: 1005-1018.
8. Zhenglu W, Hui L, Shuying ZH, Wenjuan C, Zhongyang SH,. A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. Transplant Proc 2007; 39: 3287-3291.
9. Agarwal VK, McHutchison JG, Hoofnagle JH,; for Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-470.
10. Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, et al. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl 2007; 13: 1372-1381.
11. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH,. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007; 13: 1236-1245.
12. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J,; for DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
13. Danan G, Benichou C,. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
14. Muñoz SJ, Martinez-Hernandez A, Maddrey WC,. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim- sulfamethoxazole. Hepatology 1990; 12: 342-347.
15. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, Das K,. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119 (pt 1): 576-583.
16. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD,. Trimethoprim- sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997; 92: 167-169.
17. Kowdley KV, Keeffe EB, Fawaz KA,. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 1992; 102: 2148-2150.
18. Sterneck M, Wiesner R, Ascher N, Roberts J, Ferrell L, Ludwig J, Lake J,. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14: 806-810.
19. Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R,. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20 (pt 1): 88-94.
20. Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y, et al. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nihon Med Sch 2008; 75: 187-191.
21. Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 2004; 38: 1593-1596.
22. Lovell MO, Speeg KV, Halff GA, Molina DK, Sharkey FE,. Acute hepatic allograft rejection: a comparison of patients with and without centrilobular alterations during first rejection episode. Liver Transpl 2004; 10: 369-373.
23. Hassoun Z, Shah V, Lohse CM, Pankratz VS, Petrovic LM,. Centrilobular necrosis after orthotopic liver transplantation: association with acute cellular rejection and impact on outcome. Liver Transpl 2004; 10: 480-487.
24. Khettry U, Backer A, Ayata G, Lewis WD, Jenkins RL, Gordon FD,. Centrilobular histopathologic changes in liver transplant biopsies. Hum Pathol 2002; 33: 270-276.
25. Gõmez R, Colina F, Moreno E, González I, Loinaz C, Garcia I, et al. Etiopathogenesis and prognosis of centrilobular necrosis in hepatic grafts. J Hepatol 1994; 21: 441-446.
26. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR,. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427.
27. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z,. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.